Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Prestige Biopharma Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner, YOUNGBLOOD, WILLIAM JUSTIN, and is located within 1 distinct art unit. The busiest examiner for the portfolio is YOUNGBLOOD, WILLIAM JUSTIN, who is responsible for the 1 pending office action currently active.
With 1 pending office action and 1 distinct examiner, the prosecution focus is entirely on this matter. The matching counts of 1 examiner, 1 art unit, and 1 action mean that the company's current USPTO activity is centralized. Practitioners only need to address the specific requirements of the assigned examiner within that art unit to move the case forward. This scope of pending activity reduces the complexity of managing multiple deadlines or different examiner requirements across the Biotechnology & Pharmaceuticals sector. The art unit assignment provides a technical framework for the pending case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18776613 | MUCOADHESIVE-PLGA NANOPARTICLES | YOUNGBLOOD, WILLIAM JUSTIN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18776613 | MUCOADHESIVE-PLGA NANOPARTICLES | YOUNGBLOOD, WILLIAM JUSTIN | 1645 | §102 | Non-Final OA | — | Pending | Jul 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrestige Biopharma Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Justin Youngblood has the most, with 1 of Prestige Biopharma Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
